Stevens-Johnson Syndrome
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
HLA-B,
HLA-A,
HLA-C,
PTGER3,
PARP1,
IFNG,
NEDD4,
NOS2,
ALB,
PML,
PSMC5,
PTGIS,
RB1,
VCP,
CUL4A,
CUL1,
ELMO1,
RBX1,
IKZF1,
CELF2,
COPS5,
FBXO6,
DERL1,
MIF,
NUCB1,
EP300,
CAV1,
CTNNB1,
CSF3,
IFNA2
HLA-B,
HLA-A,
HLA-C,
PTGER3,
PARP1,
IFNG,
NEDD4,
NOS2,
ALB,
PML,
PSMC5,
PTGIS,
RB1,
VCP,
CUL4A,
CUL1,
ELMO1,
RBX1,
IKZF1,
CELF2,
COPS5,
FBXO6,
DERL1,
MIF,
NUCB1,
EP300,
CAV1,
CTNNB1,
CSF3,
IFNA2,
NFKBIZ,
PSORS1C3,
POU5F1,
DDX39B,
TCF19,
UMAD1,
ATP6V1G2-DDX39B,
PSORS1C1,
HSPG2,
GNLY,
FASLG,
TLR3,
CYP2C9,
CYP3A4,
ABCB6,
HCP5,
FAS,
CCL27,
AKR1B1,
TPP1,
MICA,
IL4R,
COX8A,
CYP2C19,
IL13,
TGM1,
SCN1A,
EGFR,
EPHX1,
FDXR,
ABCB1,
CCR10,
HLA-DRB1,
MMP9,
MMP2,
IL15,
BAG6
Drugs
—
Registered!
A limited form of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area.